HighLife
- Company typePrivate
- Founded2010
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
HighLife firmographics
Firmographics- Name
- HighLife
- Legal name
- HighLife SAS
- Website
- https://highlifemedical.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
HighLife industry classification
Industry- Product category
- Transcatheter Mitral Valve Replacement Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where HighLife is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
HighLife business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others
Revenue model
- TMVR Device Sales: Pre-commercial company with CE Mark approval received January 2026. Revenue expected from sale of TSMVR devices to hospitals and cardiac centers in Europe, with future expansion to US and other markets following regulatory approvals.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
HighLife product offering
Product offeringCore offering
HighLife develops and manufactures the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System, a transcatheter device for treating symptomatic moderate-to-severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair. The product is a dual-component valve-in-ring implant delivered transfemorally via a trans-septal approach and is sold to hospitals and cardiac centers, with CE Mark approval secured in January 2026 enabling European commercial launch.
Product overview
HighLife Medical is a pre-commercial stage MedTech company developing the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) system - a novel transcatheter solution for treating moderate to severe mitral regurgitation. The system consists of a dual-component valve-in-ring design: a bovine pericardial valve that self-centers within a sub-annular ring implanted percutaneously via transfemoral transseptal approach. The product portfolio includes Standard and Clarity valve variants, with the Clarity variant designed for patients at risk of left ventricular outflow tract obstruction. The company recently received CE Mark approval (January 2026) for commercial introduction in Europe and continues US pivotal clinical trials. The system addresses patients who are unsuitable for surgery or transcatheter edge-to-edge repair (TEER).
Differentiator
Problem solved
Functional benefit
Products and services
- HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System A transcatheter mitral valve replacement system using a dual-component valve-in-ring design (bovine pericardial valve plus sub-annular ring) delivered transfemorally via a trans-septal approach. Indicated for adult patients with symptomatic moderate-severe or severe mitral regurgitation who are unsuitable for surgical repair/replacement or transcatheter edge-to-edge repair (TEER). Available in Standard and Clarity configurations (with the Clarity variant for patients at risk of LVOTO) and in Large Annulus Valve sizes accommodating annuli up to 53 mm. Sold to hospitals and structural heart centers.
Quantifiable outcome
- 90% technical success rate in clinical data
- +5 more outcomes
Companies that use HighLife
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
HighLife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
HighLife partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Peijia MedicalcoreLicense and technology transfer agreement for trans-septal mitral valve replacement in Greater China. HighLife granted Peijia exclusive license for manufacturing, development, and commercialization in the greater China region. Peijia pays upfront fee and milestone payments. A joint review committee oversees development and commercialization. The partnership enabled first clinical use of HighLife technology in China within 12 months of agreement.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
HighLife competitors and assessment
Company assessmentBroad incumbents
- Edwards Lifesciences: Major structural heart medtech incumbent with PASCAL and SAPIEN M3 transcatheter mitral programs. Comparable to HighLife as both target transcatheter mitral regurgitation treatment, though Edwards operates across the broader structural heart portfolio including TAVR leadership.
- Medtronic: Global medtech leader developing Intrepid TMVR system for mitral regurgitation. Comparable as a direct TMVR competitor with deeper resources, established structural heart sales force, and extensive clinical evidence program. Acquired CoreValve (HighLife founder's previous company) for $700M+.
- Abbott: Structural heart incumbent with Tendyne transcatheter mitral valve (acquired 2015) and MitraClip market leadership. Directly competes in the mitral regurgitation treatment space with significant commercial infrastructure and physician relationships.
Emerging players
- Venus MedTech: Chinese structural heart company developing Cardiovalve transcatheter mitral valve replacement system. Comparable as emerging TMVR player with CE Mark approval and progress toward global commercialization, including potential APAC market overlap with HighLife.
- 4C Medical Technologies: Early-stage medical device company developing AltaValve transcatheter mitral valve replacement technology. Directly comparable as emerging TMVR competitor with novel approach to mitral regurgitation treatment in clinical trials.
- Cephea Valve Technologies: TMVR developer acquired by Abbott in 2019 for $300M+ upfront. Provides a comparable exit reference for HighLife as both focused on transcatheter mitral valve replacement technology, though Cephea was acquired pre-commercialization.
- Neovasc: Developer of Tiara transcatheter mitral valve replacement, acquired by Edwards Lifesciences. Comparable as TMVR technology that was acquired by a major incumbent, providing another recent exit reference for HighLife's technology category.
- CroiValve: Early-stage medtech developing transcatheter tricuspid and mitral valve technologies. Comparable as emerging structural heart company developing transcatheter valve replacement solutions with similar clinical and regulatory pathway.
- CardioMech: Norwegian medical device company developing transcatheter mitral valve repair technology. Comparable as European-based emerging structural heart company with similar regulatory pathway and target patient population.
Others
- Peijia Medical: Chinese structural heart company that is both a strategic partner (Greater China licensee for HighLife) and adjacent peer developing its own transcatheter valve technologies including TaurusTrio for mitral regurgitation. Provides both partnership and competitive context for HighLife.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
HighLife social profiles
Digital presenceHighLife compliance and trust
Trust signalCompliance3 records
HighLife financial estimates
Financial estimateRevenue estimate
Valuation estimate
HighLife leadership team
Management profileNumber of profiles
Profiles1 record
HighLife subsidiaries and ownership
Company hierarchySubsidiaries1 record
HighLife funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HighLife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HighLife
What does HighLife do?
HighLife develops and manufactures the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System, a transcatheter device for treating symptomatic moderate-to-severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair. The product is a dual-component valve-in-ring implant delivered transfemorally via a trans-septal approach and is sold to hospitals and cardiac centers, with CE Mark approval secured in January 2026 enabling European commercial launch.
Is HighLife a public or private company?
HighLife is a private company. It is classified as venture growth investor backed and is currently operating.
When was HighLife founded?
HighLife was founded in 2010. It employs 11 to 50 people.
Where is HighLife based?
HighLife is headquartered in Paris, France, in the Europe region.
How does HighLife make money?
One revenue line is on record: TMVR Device Sales.
Who are HighLife's main competitors?
Broad incumbents on record are Edwards Lifesciences, Medtronic and Abbott. Emerging players are Venus MedTech, 4C Medical Technologies, Cephea Valve Technologies, Neovasc, CroiValve and CardioMech. Peijia Medical is listed as an others.
Does HighLife have an API?
No public API is recorded for HighLife.
What industry is HighLife in?
HighLife's product category is Transcatheter Mitral Valve Replacement Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339112 and its SIC code is 3841.